Please assess the completion status of the following clinical trial:

Trial Title: Bismuth for PCAB-based H. Pylori Eradication

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Gastroscopy can be performed~* H. pylori test and pathological analysis can be performed~Exclusion Criteria:~* Age \< 20 or \> 80 years~* Anemia (serum hemoglobin level \< 10 g/dL)~* Severe systemic disease~* Advanced chronic liver disease~* Use of certain medications, including proton pump inhibitors, H2- receptor antagonists, or antibiotics~* History of H. pylori eradication~* Drug allergy to antibiotics~* History of gastric surgery~* Recent history of upper gastrointestinal bleeding

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Non-bismuth group (Type: None): Tegoprazan 50 mg bid, amoxicillin 1000 mg bid, clarithromycin 500 mg bid for 14 days
- Bismuth group (Type: None): Tegoprazan 50 mg bid, amoxicillin 1000 mg bid, clarithromycin 500 mg bid, tripotassium dicitrate bismuthate (DENOL) 300 mg bid for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).